Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review

Cancer Gene Ther. 2020 Apr;27(3-4):116-124. doi: 10.1038/s41417-019-0116-8. Epub 2019 Jun 20.

Abstract

Gene therapy using CRISPR Cas9 technique is rapidly gaining popularity among the scientific community primarily because of its versatility, cost-effectiveness, and high efficacy. While the laboratory-based experiments and findings making use of CRISPR as a gene editing tool are available in ample amounts, the question arises that how much of these findings are actually translatable into measures helping in combating particular disease conditions. In this review, we highlight the important studies and findings done till now in the perspective of lung cancer with an in-depth analysis of various clinical trials associated with the use of CRISPR Cas9 technology in the field of cancer research.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor / genetics
  • CRISPR-Cas Systems / genetics*
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Cell Line, Tumor
  • Chromosomes, Human, Pair 3 / genetics
  • Chromosomes, Human, Pair 5 / genetics
  • Chromosomes, Human, Pair 9 / genetics
  • Clinical Trials as Topic
  • Gene Editing / methods
  • Gene Knockout Techniques
  • Genetic Therapy / methods*
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / genetics
  • Lung Neoplasms / therapy*
  • Mice
  • Mutation
  • Sequence Deletion
  • Translational Research, Biomedical / methods*
  • Tumor Suppressor Proteins / genetics

Substances

  • Biomarkers, Tumor
  • Tumor Suppressor Proteins